LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
2nd June 2021
Portfolio
This post references, or is about LogicBio. Find out more by clicking below